Advanced progress of the relationship between PCSK9 monoclonal antibodies and hyperglycemic adverse events.

ABSTRACT:

Purpose of review

Long-term use of statins had been confirmed to cause an increase in hyperglycemic adverse events (HAEs), whose mechanism has been well understood. Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (PCSK9-mAbs), a kind of new lipid-lowering drug, can effectively reduce plasma low-density lipoprotein cholesterol levels in patients with CHD and have been widely used. However, animal experiments, Mendelian randomization studies, clinical researches and Meta-analyses which focused on the relationship between PCSK9-mAbs and HAEs had reached different conclusions, which has attracted great attention from clinicians.

Recent findings

The newest FOURIER-OLE randomized controlled trial followed PCSK9-mAbs users for over 8 years, whose results

SUBMITTER: Zhang R 

PROVIDER: S-EPMC10330718 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature